Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary) ; Eltrombopag
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Acronyms ASTUTE
- Sponsors Eisai Inc
- 08 Dec 2020 Results of a pooled analysis assessing the efficacy profile of AVA across its clinical development program (comprised of 4 phase 2 and 3 studies, CL-003,CL-004, study 302 and study 305), presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results assessing the preclinical findings and screen for atrophic gastritis, gastric biomarkers (gastrin, gastrin-17, and pepsinogen I/II [PG-I/PG-II]) from 2 Phase 3 trials (NCT01438840 and NCT01433978) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 08 Apr 2016 Treatment arms changed from 2 to 3 with addition of Open-label Extension.